Mergers and Acquisitions

GSK looking to sell part of antibiotics business

03-Mar-2020 By Vassia Barba

GSK reportedly exploring the sale of part of its antibiotics business, as it refocuses its operations towards R&D.

Roche takes Bicycle tech for drug discovery spin

27-Feb-2020 By Ben Hargreaves

Genentech and Bicycle partner for the development of small molecule, immuno-oncology targets.

Grifols picks up bankrupt antibiotics developer’s portfolio

25-Feb-2020 By Vassia Barba

Grifols set to purchase all assets of Aradigm, including its Phase III antibiotic for respiratory diseases, after the developer filed for bankruptcy.

Merck KGaA sells allergy business to focus on innovative medicine

24-Feb-2020 By Ben Hargreaves

Dermapharm will pick up the business unit for an unspecified fee, whilst Merck will retain the development of its adrenaline autoinjector project.

Dr Reddy’s picks up portfolio and facility from rival for $259m

17-Feb-2020 By Ben Hargreaves

Wockhardt sells part of its domestic business to fund growth in international markets and to develop its biosimilar business.

Sterling expects further HPAPI demand, looks for buy-out opportunities

15-Jan-2020 By Vassia Barba

Sterling continues expansion and lines up further acquisitions, as the HPAPI market continues to see increasing demand, a company executive says.

Alcami sells Dutch API facility to MercachemSyncom

14-Jan-2020 By Ben Hargreaves

Alcami downsizes in Europe through the sale of its API facility to MercachemSyncom, as it expands its presence in North America.

ANI picks up US generics portfolio of Amerigen

13-Jan-2020 By Ben Hargreaves

ANI acquires the 23 generic products from Amerigen to expand its commercial offering in the US.

One in, one out: Esteve pivots to specialty products

09-Jan-2020 By Ben Hargreaves

Esteve announces that it will acquire Riemser, two weeks after it revealed that it would be divesting its generics division.

Amneal invests $340m in generics distributor

16-Dec-2019 By Vassia Barba

Amneal announces acquisition of 65.1% majority interest of generics distributing company, AvKARE, boosting its presence in the generics and federal healthcare market.

Icon braces for BMS-Celgene merger to slow RFP activity

02-Dec-2019 By Nick Taylor

Icon prepares for slowdown in request for proposal (RFP) activity, as BMS and Celgene merge.

Asahi Kasei in $1.3bn bid to access US pharma market

28-Nov-2019 By Ben Hargreaves

Asahi Kasei has a bid accepted for oral dose specialist, Veloxis, with one eye on gaining a position in the US market.

Recro spins out Baudax to boost CDMO focus

28-Nov-2019 By Vassia Barba

Recro Pharma announces the separation of its acute care business to launch Baudax Bio as a developer of products, including non-opioid analgesics, to concentrate on its CDMO business.